DeepMed Research

RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Quality of Life Outcomes in Spinal Cord Stimulation

Terminated

Conditions: Neuropathic Pain
Low Back Pain

Interventions: Device: Spinal Cord Stimulation

First Posted Date: 2017-08-15

Last Posted Date: 2018-07-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 6

Registration Number: NCT03249922

Locations: 🇺🇸
Neurologic Institute of New Jersey, Newark, New Jersey, United States

Assuring Patient-centered Literacy Promotion for Underserved Children Study

Not Applicable

Completed

Conditions: Literacy

Interventions: Behavioral: Intervention Group

First Posted Date: 2017-08-08

Last Posted Date: 2020-02-18

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 160

Registration Number: NCT03242850

Locations: 🇺🇸
Eric B. Chandler Health Center, New Brunswick, New Jersey, United States

Vaccination Education Through Pharmacists and Senior Centers (VEPSC)

Not Applicable

Completed

Conditions: Pneumonia, Bacterial
Influenza
Infectious Disease
Zoster; Herpes

Interventions: Behavioral: Pharmacist-led Intervention (PHARM)
Behavioral: Peer-led Intervention (PEER)

First Posted Date: 2017-08-04

Last Posted Date: 2020-07-01

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 335

Registration Number: NCT03239665

Locations: 🇺🇸
Rutgers University, Piscataway, New Jersey, United States

Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers

Completed

Conditions: Genetic Predisposition
GBA Gene Mutation
Parkinson Disease
Parkinson
Cognitive Decline

Interventions: Other: cognitive assessments

First Posted Date: 2017-07-31

Last Posted Date: 2024-11-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 150

Registration Number: NCT03234478

Locations: 🇺🇸
Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Remote Ischemic Conditioning in Abdominal Surgery

Not Applicable

Conditions: Pancreatic Diseases
Gastrointestinal Disease
Laparotomy
Laparoscopy
Retroperitoneal Disease
Pelvis Disease
Liver Diseases
Complication of Surgical Procedure
Urologic Diseases

Interventions: Procedure: No Remote ischemic conditioning
Procedure: Remote ischemic conditioning

First Posted Date: 2017-07-31

Last Posted Date: 2019-02-25

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 100

Registration Number: NCT03234543

Locations: 🇺🇸
University Hospital, Newark, New Jersey, United States

Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer

Not Applicable

Completed

Conditions: Stage I Breast Cancer
Stage I Prostate Cancer
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage II Colorectal Cancer AJCC v7
Stage II Prostate Cancer
Stage IIC Colorectal Cancer AJCC v7
Stage I Colorectal Cancer AJCC v6 and v7
Stage IIA Breast Cancer
Stage IIB Colorectal Cancer AJCC v7

Interventions: Other: Internet-Based Intervention
Other: Informational Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2017-07-28

Last Posted Date: 2022-08-29

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 535

Registration Number: NCT03233555

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Phase 1

Completed

Conditions: Recurrent Malignant Solid Neoplasm
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IV Lymphoma
Recurrent Bladder Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Lymphoma
Stage III Bladder Cancer
Stage III Lymphoma
Stage III Skin Melanoma

Interventions: Drug: Enzyme Inhibitor Therapy
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: Pembrolizumab

First Posted Date: 2017-07-25

Last Posted Date: 2023-12-06

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 14

Registration Number: NCT03229278

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment

Not Applicable

Completed

Conditions: Malignant Neoplasm
Esophagitis
Mucositis

Interventions: Dietary Supplement: Nutritional Supplementation
Other: Questionnaire Administration

First Posted Date: 2017-07-24

Last Posted Date: 2017-11-17

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 30

Registration Number: NCT03228147

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Effect of Pharmacists Treating Diabetes in a FQHC

Not Applicable

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: Pharmacist review of therapy

First Posted Date: 2017-04-28

Last Posted Date: 2018-11-16

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 239

Registration Number: NCT03134170

Locations: 🇺🇸
Henry J Austin Health Clinic, Trenton, New Jersey, United States

Novel Gallium 68 Citrate in Orthopedic Infections

Phase 2

Terminated

Conditions: Joint Prosthesis

Interventions: Drug: 68-Gallium citrate PET/CT scan
Drug: 18F FDG PET/CT scan

First Posted Date: 2017-04-21

Last Posted Date: 2021-04-15

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 1

Registration Number: NCT03123289

Locations: 🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy